Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Refrensi

DOI: https://doi.org/10.33650/jkp.v9i2.2767

Authors (s)


(1) * Setiyo Adi Nugroho   (Universitas Nurul Jadid, Probolinggo)  
        Indonesia
(2)  Indra Nur Hidayat   (Universitas Nurul Jadid, Probolinggo)  
        Indonesia
(*) Corresponding Author

Abstract


Various strategies and development of the Covid-19 vaccine have been carried out for the control of the Covid-19 pandemic. Various vaccines have undergone clinical trials with promising results in various countries. The effectiveness and safety and short- and long-term side effects of vaccines are a major concern in clinical trials in these strategies and developments. Purpose: The purpose of this study is to find out the effectiveness and safety of the Covid-19 vaccine so that it can inform and increase public confidence in the Covid-19 vaccine through a reference study approach. Method: The research method we use here is a reference study using electronic databases through journals from international and national. Google Scholar, science direx, elsiver, Pubmed are used as the main Journal database for this reference study. Results: From the results of reference studies found that all vaccines in clinical trials have promising effectiveness and safety. The Pfizer-BiONTech vaccine is a vaccine that has a good level of effectiveness and safety with a value of 94.6% and does not cause serious side effects. Double-dose vaccination further improves the immune response in younger and older adults. Conclusion: The Covid-19 vaccine in clinical trials all demonstrates promising immunogenicity with varying levels of protective effectiveness and an acceptable safety profile.



Keywords

Covid-19. Vaccine. Effectiveness. Safety



Full Text: PDF



References


ANADOLU, A. 2021. Decision Based on Results of Country’s Phase III Trials That Put Estimated Vaccine Efficacy at 65.3%, Says Official. [Online]. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy [Accessed 24 Juli 2021].

ANDERSON, E. J., ROUPHAEL, N. G., WIDGE, A. T., JACKSON, L. A., ROBERTS, P. C., MAKHENE, M., CHAPPELL, J. D., DENISON, M. R., STEVENS, L. J., PRUIJSSERS, A. J., MCDERMOTT, A. B., FLACH, B., LIN, B. C., DORIA-ROSE, N. A., O'DELL, S., SCHMIDT, S. D., CORBETT, K. S., SWANSON, P. A., 2ND, PADILLA, M., NEUZIL, K. M., BENNETT, H., LEAV, B., MAKOWSKI, M., ALBERT, J., CROSS, K., EDARA, V. V., FLOYD, K., SUTHAR, M. S., MARTINEZ, D. R., BARIC, R., BUCHANAN, W., LUKE, C. J., PHADKE, V. K., ROSTAD, C. A., LEDGERWOOD, J. E., GRAHAM, B. S. & BEIGEL, J. H. 2020a. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med, 383, 2427-2438.

ANDERSON, R. M., VEGVARI, C., TRUSCOTT, J. & COLLYER, B. S. 2020b. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet, 396, 1614-1616.

ANDREAS, G., THOMAS, T., THEODORE, E. W., KARIN, W., PAUL, K. & SABINE, E. 2021. A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination. Research Square.

BONAM, S. R., KOTLA, N. G., BOHARA, R. A., ROCHEV, Y., WEBSTER, T. J. & BAYRY, J. 2021. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano today, 36, 101051-101051.

BUSS, L. F., PRETE, C. A., JR., ABRAHIM, C. M. M., MENDRONE, A., JR., SALOMON, T., DE ALMEIDA-NETO, C., FRANÇA, R. F. O., BELOTTI, M. C., CARVALHO, M., COSTA, A. G., CRISPIM, M. A. E., FERREIRA, S. C., FRAIJI, N. A., GURZENDA, S., WHITTAKER, C., KAMAURA, L. T., TAKECIAN, P. L., DA SILVA PEIXOTO, P., OIKAWA, M. K., NISHIYA, A. S., ROCHA, V., SALLES, N. A., DE SOUZA SANTOS, A. A., DA SILVA, M. A., CUSTER, B., PARAG, K. V., BARRAL-NETTO, M., KRAEMER, M. U. G., PEREIRA, R. H. M., PYBUS, O. G., BUSCH, M. P., CASTRO, M. C., DYE, C., NASCIMENTO, V. H., FARIA, N. R. & SABINO, E. C. 2021. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 371, 288-292.

CALLAWAY, E. 2021. Could New Covid Variants Undermine Vaccines? Labs Scramble to Find Out. Nature.

CDC. 2021a. COVID-19 and Your Health [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/your-health/index.html [Accessed 23 Juli 2021].

CDC. 2021b. Safety of COVID-19 Vaccines [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html#:~:text=COVID%2D19%20vaccines%20are%20safe,vaccine%20as%20soon%20as%20possible. [Accessed 23 Juli 2021].

CHEN, C., CHEN, C., YAN, J. T., ZHOU, N., ZHAO, J. P. & WANG, D. W. 2020. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi, 48, 567-571.

CLERKIN, K. J., FRIED, J. A., RAIKHELKAR, J., SAYER, G., GRIFFIN, J. M., MASOUMI, A., JAIN, S. S., BURKHOFF, D., KUMARAIAH, D., RABBANI, L., SCHWARTZ, A. & URIEL, N. 2020. COVID-19 and Cardiovascular Disease. Circulation, 141, 1648-1655.

CLINICALTRIALS.GOV. 2021. Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above [Online]. Available: https://www.clinicaltrials.gov/ct2/show/NCT04526990 [Accessed 24 Juli 2021].

DROSTEN, C., GÜNTHER, S., PREISER, W., VAN DER WERF, S., BRODT, H. R., BECKER, S., RABENAU, H., PANNING, M., KOLESNIKOVA, L., FOUCHIER, R. A., BERGER, A., BURGUIÈRE, A. M., CINATL, J., EICKMANN, M., ESCRIOU, N., GRYWNA, K., KRAMME, S., MANUGUERRA, J. C., MÜLLER, S., RICKERTS, V., STÜRMER, M., VIETH, S., KLENK, H. D., OSTERHAUS, A. D., SCHMITZ, H. & DOERR, H. W. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 348, 1967-76.

ELLA, R., REDDY, S., JOGDAND, H., SARANGI, V., GANNERU, B., PRASAD, S., DAS, D., RAJU, D., PRATURI, U., SAPKAL, G., YADAV, P., REDDY, P., VERMA, S., SINGH, C., REDKAR, S. V., GILLURKAR, C. S., KUSHWAHA, J. S., MOHAPATRA, S., BHATE, A., RAI, S., PANDA, S., ABRAHAM, P., GUPTA, N., ELLA, K., BHARGAVA, B. & VADREVU, K. M. 2021a. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis, 21, 950-961.

ELLA, R., VADREVU, K. M., JOGDAND, H., PRASAD, S., REDDY, S., SARANGI, V., GANNERU, B., SAPKAL, G., YADAV, P., ABRAHAM, P., PANDA, S., GUPTA, N., REDDY, P., VERMA, S., KUMAR RAI, S., SINGH, C., REDKAR, S. V., GILLURKAR, C. S., KUSHWAHA, J. S., MOHAPATRA, S., RAO, V., GULERIA, R., ELLA, K. & BHARGAVA, B. 2021b. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 21, 637-646.

FDA. 2020. Vaccines and Related Biological Products Advisory Committee [Online]. Available: https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee [Accessed 20 Juli 2020].

FDA. 2021. Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Announcement [Online]. Available: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-february-26-2021-meeting-announcement [Accessed 24 Juli 2021].

FOLEGATTI, P. M., EWER, K. J., ALEY, P. K., ANGUS, B., BECKER, S., BELIJ-RAMMERSTORFER, S., BELLAMY, D., BIBI, S., BITTAYE, M., CLUTTERBUCK, E. A., DOLD, C., FAUST, S. N., FINN, A., FLAXMAN, A. L., HALLIS, B., HEATH, P., JENKIN, D., LAZARUS, R., MAKINSON, R., MINASSIAN, A. M., POLLOCK, K. M., RAMASAMY, M., ROBINSON, H., SNAPE, M., TARRANT, R., VOYSEY, M., GREEN, C., DOUGLAS, A. D., HILL, A. V. S., LAMBE, T., GILBERT, S. C. & POLLARD, A. J. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 396, 467-478.

GUO, W., LI, M., DONG, Y., ZHOU, H., ZHANG, Z., TIAN, C., QIN, R., WANG, H., SHEN, Y., DU, K., ZHAO, L., FAN, H., LUO, S. & HU, D. 2020. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev, e3319.

HAAS, E. J., ANGULO, F. J., MCLAUGHLIN, J. M., ANIS, E., SINGER, S. R., KHAN, F., BROOKS, N., SMAJA, M., MIRCUS, G., PAN, K., SOUTHERN, J., SWERDLOW, D. L., JODAR, L., LEVY, Y. & ALROY-PREIS, S. 2021. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, 397, 1819-1829.

HAKAM. 2021. Understanding the Importance of Covid-19 Vaccines. News Report.

HE, X., CHANDRASHEKAR, A., ZAHN, R., WEGMANN, F., YU, J., MERCADO, N. B., MCMAHAN, K., MARTINOT, A. J., PIEDRA-MORA, C., BEECY, S., DUCAT, S., CHAMANZA, R., HUBER, S. R., VAN DER FITS, L., BORDUCCHI, E. N., LIFTON, M., LIU, J., NAMPANYA, F., PATEL, S., PETER, L., TOSTANOSKI, L. H., PESSAINT, L., VAN RY, A., FINNEYFROCK, B., VELASCO, J., TEOW, E., BROWN, R., COOK, A., ANDERSEN, H., LEWIS, M. G., SCHUITEMAKER, H. & BAROUCH, D. H. 2021. Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques. bioRxiv.

HO, J. S. Y., TAMBYAH, P. A. & SIA, C. H. 2020. A Call for Vaccine Against COVID-19: Implications for Cardiovascular Morbidity and Healthcare Utilization. Cardiovasc Drugs Ther, 34, 585-587.

JACKSON, L. A., ANDERSON, E. J., ROUPHAEL, N. G., ROBERTS, P. C., MAKHENE, M., COLER, R. N., MCCULLOUGH, M. P., CHAPPELL, J. D., DENISON, M. R., STEVENS, L. J., PRUIJSSERS, A. J., MCDERMOTT, A., FLACH, B., DORIA-ROSE, N. A., CORBETT, K. S., MORABITO, K. M., O'DELL, S., SCHMIDT, S. D., SWANSON, P. A., 2ND, PADILLA, M., MASCOLA, J. R., NEUZIL, K. M., BENNETT, H., SUN, W., PETERS, E., MAKOWSKI, M., ALBERT, J., CROSS, K., BUCHANAN, W., PIKAART-TAUTGES, R., LEDGERWOOD, J. E., GRAHAM, B. S. & BEIGEL, J. H. 2020. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med, 383, 1920-1931.

KATULANDA, P., DISSANAYAKE, H. A., RANATHUNGA, I., RATNASAMY, V., WIJEWICKRAMA, P. S. A., YOGENDRANATHAN, N., GAMAGE, K. K. K., DE SILVA, N. L., SUMANATILLEKE, M., SOMASUNDARAM, N. P. & MATTHEWS, D. R. 2020. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia, 63, 1440-1452.

KEECH, C., ALBERT, G., CHO, I., ROBERTSON, A., REED, P., NEAL, S., PLESTED, J. S., ZHU, M., CLONEY-CLARK, S., ZHOU, H., SMITH, G., PATEL, N., FRIEMAN, M. B., HAUPT, R. E., LOGUE, J., MCGRATH, M., WESTON, S., PIEDRA, P. A., DESAI, C., CALLAHAN, K., LEWIS, M., PRICE-ABBOTT, P., FORMICA, N., SHINDE, V., FRIES, L., LICKLITER, J. D., GRIFFIN, P., WILKINSON, B. & GLENN, G. M. 2020. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med, 383, 2320-2332.

KWONG, J. C., SCHWARTZ, K. L., CAMPITELLI, M. A., CHUNG, H., CROWCROFT, N. S., KARNAUCHOW, T., KATZ, K., KO, D. T., MCGEER, A. J., MCNALLY, D., RICHARDSON, D. C., ROSELLA, L. C., SIMOR, A., SMIEJA, M., ZAHARIADIS, G. & GUBBAY, J. B. 2018. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med, 378, 345-353.

LOGUNOV, D. Y., DOLZHIKOVA, I. V., SHCHEBLYAKOV, D. V., TUKHVATULIN, A. I., ZUBKOVA, O. V., DZHARULLAEVA, A. S., KOVYRSHINA, A. V., LUBENETS, N. L., GROUSOVA, D. M., EROKHOVA, A. S., BOTIKOV, A. G., IZHAEVA, F. M., POPOVA, O., OZHAROVSKAYA, T. A., ESMAGAMBETOV, I. B., FAVORSKAYA, I. A., ZRELKIN, D. I., VORONINA, D. V., SHCHERBININ, D. N., SEMIKHIN, A. S., SIMAKOVA, Y. V., TOKARSKAYA, E. A., EGOROVA, D. A., SHMAROV, M. M., NIKITENKO, N. A., GUSHCHIN, V. A., SMOLYARCHUK, E. A., ZYRYANOV, S. K., BORISEVICH, S. V., NARODITSKY, B. S. & GINTSBURG, A. L. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 397, 671-681.

LOGUNOV, D. Y., DOLZHIKOVA, I. V., ZUBKOVA, O. V., TUKHVATULIN, A. I., SHCHEBLYAKOV, D. V., DZHARULLAEVA, A. S., GROUSOVA, D. M., EROKHOVA, A. S., KOVYRSHINA, A. V., BOTIKOV, A. G., IZHAEVA, F. M., POPOVA, O., OZHAROVSKAYA, T. A., ESMAGAMBETOV, I. B., FAVORSKAYA, I. A., ZRELKIN, D. I., VORONINA, D. V., SHCHERBININ, D. N., SEMIKHIN, A. S., SIMAKOVA, Y. V., TOKARSKAYA, E. A., LUBENETS, N. L., EGOROVA, D. A., SHMAROV, M. M., NIKITENKO, N. A., MOROZOVA, L. F., SMOLYARCHUK, E. A., KRYUKOV, E. V., BABIRA, V. F., BORISEVICH, S. V., NARODITSKY, B. S. & GINTSBURG, A. L. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, 396, 887-897.

MADHAV, N., OPPENHEIM, B., GALLIVAN, M., MULEMBAKANI, P., RUBIN, E. & WOLFE, N. 2017. Pandemics: Risks, Impacts, and Mitigation. In: JAMISON, D. T., GELBAND, H., HORTON, S., JHA, P., LAXMINARAYAN, R., MOCK, C. N. & NUGENT, R. (eds.) Disease Control Priorities: Improving Health and Reducing Poverty. Washington (DC): The International Bank for Reconstruction and Development / The World Bank

© 2018 International Bank for Reconstruction and Development / The World Bank.

MADJID, M., SAFAVI-NAEINI, P., SOLOMON, S. D. & VARDENY, O. 2020. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol, 5, 831-840.

MAHASE, E. 2021. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. Bmj, 372, n296.

MERCADO, N. B., ZAHN, R., WEGMANN, F., LOOS, C., CHANDRASHEKAR, A., YU, J., LIU, J., PETER, L., MCMAHAN, K., TOSTANOSKI, L. H., HE, X., MARTINEZ, D. R., RUTTEN, L., BOS, R., VAN MANEN, D., VELLINGA, J., CUSTERS, J., LANGEDIJK, J. P., KWAKS, T., BAKKERS, M. J. G., ZUIJDGEEST, D., ROSENDAHL HUBER, S. K., ATYEO, C., FISCHINGER, S., BURKE, J. S., FELDMAN, J., HAUSER, B. M., CARADONNA, T. M., BONDZIE, E. A., DAGOTTO, G., GEBRE, M. S., HOFFMAN, E., JACOB-DOLAN, C., KIRILOVA, M., LI, Z., LIN, Z., MAHROKHIAN, S. H., MAXFIELD, L. F., NAMPANYA, F., NITYANANDAM, R., NKOLOLA, J. P., PATEL, S., VENTURA, J. D., VERRINGTON, K., WAN, H., PESSAINT, L., VAN RY, A., BLADE, K., STRASBAUGH, A., CABUS, M., BROWN, R., COOK, A., ZOUANTCHANGADOU, S., TEOW, E., ANDERSEN, H., LEWIS, M. G., CAI, Y., CHEN, B., SCHMIDT, A. G., REEVES, R. K., BARIC, R. S., LAUFFENBURGER, D. A., ALTER, G., STOFFELS, P., MAMMEN, M., VAN HOOF, J., SCHUITEMAKER, H. & BAROUCH, D. H. 2020. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 586, 583-588.

MOUSTSEN-HELMS, I. R., EMBORG, H.-D., NIELSEN, J., NIELSEN, K. F., KRAUSE, T. G., MØLBAK, K., MØLLER, K. L., BERTHELSEN, A.-S. N. & VALENTINER-BRANTH, P. 2021. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. medRxiv, 2021.03.08.21252200.

MULLIGAN, M. J., LYKE, K. E., KITCHIN, N., ABSALON, J., GURTMAN, A., LOCKHART, S., NEUZIL, K., RAABE, V., BAILEY, R., SWANSON, K. A., LI, P., KOURY, K., KALINA, W., COOPER, D., FONTES-GARFIAS, C., SHI, P. Y., TÜRECI, Ö., TOMPKINS, K. R., WALSH, E. E., FRENCK, R., FALSEY, A. R., DORMITZER, P. R., GRUBER, W. C., ŞAHIN, U. & JANSEN, K. U. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586, 589-593.

NUPUS, H. 2021. Indonesia approves China’s CoronaVac for emergency use [Online]. Available: https://www.aa.com.tr/en/asia-pacific/indonesia-approves-china-s-coronavac-for-emergency-use/2105881 [Accessed 25 Juli 2021].

PARDI, N., HOGAN, M. J. & WEISSMAN, D. 2020. Recent advances in mRNA vaccine technology. Curr Opin Immunol, 65, 14-20.

POLACK, F. P., THOMAS, S. J., KITCHIN, N., ABSALON, J., GURTMAN, A., LOCKHART, S., PEREZ, J. L., PÉREZ MARC, G., MOREIRA, E. D., ZERBINI, C., BAILEY, R., SWANSON, K. A., ROYCHOUDHURY, S., KOURY, K., LI, P., KALINA, W. V., COOPER, D., FRENCK, R. W., JR., HAMMITT, L. L., TÜRECI, Ö., NELL, H., SCHAEFER, A., ÜNAL, S., TRESNAN, D. B., MATHER, S., DORMITZER, P. R., ŞAHIN, U., JANSEN, K. U. & GRUBER, W. C. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 383, 2603-2615.

PORTER, K. R. & RAVIPRAKASH, K. 2017. DNA Vaccine Delivery and Improved Immunogenicity. Curr Issues Mol Biol, 22, 129-138.

RAMASAMY, M. N., MINASSIAN, A. M., EWER, K. J., FLAXMAN, A. L., FOLEGATTI, P. M., OWENS, D. R., VOYSEY, M., ALEY, P. K., ANGUS, B., BABBAGE, G., BELIJ-RAMMERSTORFER, S., BERRY, L., BIBI, S., BITTAYE, M., CATHIE, K., CHAPPELL, H., CHARLTON, S., CICCONI, P., CLUTTERBUCK, E. A., COLIN-JONES, R., DOLD, C., EMARY, K. R. W., FEDOSYUK, S., FUSKOVA, M., GBESEMETE, D., GREEN, C., HALLIS, B., HOU, M. M., JENKIN, D., JOE, C. C. D., KELLY, E. J., KERRIDGE, S., LAWRIE, A. M., LELLIOTT, A., LWIN, M. N., MAKINSON, R., MARCHEVSKY, N. G., MUJADIDI, Y., MUNRO, A. P. S., PACURAR, M., PLESTED, E., RAND, J., RAWLINSON, T., RHEAD, S., ROBINSON, H., RITCHIE, A. J., ROSS-RUSSELL, A. L., SAICH, S., SINGH, N., SMITH, C. C., SNAPE, M. D., SONG, R., TARRANT, R., THEMISTOCLEOUS, Y., THOMAS, K. M., VILLAFANA, T. L., WARREN, S. C., WATSON, M. E. E., DOUGLAS, A. D., HILL, A. V. S., LAMBE, T., GILBERT, S. C., FAUST, S. N. & POLLARD, A. J. 2021. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, 396, 1979-1993.

REUTERS, S. 2021. UPDATE 2-China's Sinovac defends COVID-19 vaccine after disappointing Brazil data [Online]. Available: https://www.reuters.com/article/health-coronavirus-malaysia-idCNL1N2JO0O9 [Accessed 25 Juli 2021].

ROTHAN, H. A. & BYRAREDDY, S. N. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 109, 102433.

SADOFF, J., LE GARS, M., SHUKAREV, G., HEERWEGH, D., TRUYERS, C., DE GROOT, A. M., STOOP, J., TETE, S., VAN DAMME, W., LEROUX-ROELS, I., BERGHMANS, P. J., KIMMEL, M., VAN DAMME, P., DE HOON, J., SMITH, W., STEPHENSON, K. E., DE ROSA, S. C., COHEN, K. W., MCELRATH, M. J., CORMIER, E., SCHEPER, G., BAROUCH, D. H., HENDRIKS, J., STRUYF, F., DOUOGUIH, M., VAN HOOF, J. & SCHUITEMAKER, H. 2021. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med, 384, 1824-1835.

SAHIN, U., MUIK, A., DERHOVANESSIAN, E., VOGLER, I., KRANZ, L. M., VORMEHR, M., BAUM, A., PASCAL, K., QUANDT, J., MAURUS, D., BRACHTENDORF, S., LÖRKS, V., SIKORSKI, J., HILKER, R., BECKER, D., ELLER, A. K., GRÜTZNER, J., BOESLER, C., ROSENBAUM, C., KÜHNLE, M. C., LUXEMBURGER, U., KEMMER-BRÜCK, A., LANGER, D., BEXON, M., BOLTE, S., KARIKÓ, K., PALANCHE, T., FISCHER, B., SCHULTZ, A., SHI, P. Y., FONTES-GARFIAS, C., PEREZ, J. L., SWANSON, K. A., LOSCHKO, J., SCULLY, I. L., CUTLER, M., KALINA, W., KYRATSOUS, C. A., COOPER, D., DORMITZER, P. R., JANSEN, K. U. & TÜRECI, Ö. 2020. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature, 586, 594-599.

SATGASCOVID-19. 2020a. Mengapa Vaksinasi di Perlukan? [Online]. Available: https://covid19.go.id/masyarakat-umum/mengapa-vaksinasi-covid-19-diperlukan-2 [Accessed 23 Juli 2021].

SATGASCOVID-19. 2020b. Survei Penerimaan Vaksin COVID-19 di Indonesia [Online]. Available: https://covid19.go.id/p/hasil-kajian/covid-19-vaccine-acceptance-survey-indonesia [Accessed 22 Juli 2021].

SMEETH, L., THOMAS, S. L., HALL, A. J., HUBBARD, R., FARRINGTON, P. & VALLANCE, P. 2004. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med, 351, 2611-8.

SOUMYA, R. S., UNNI, T. G. & RAGHU, K. G. 2021. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. Cardiovasc Drugs Ther, 35, 411-425.

STEPHENSON, K. E., LE GARS, M., SADOFF, J., DE GROOT, A. M., HEERWEGH, D., TRUYERS, C., ATYEO, C., LOOS, C., CHANDRASHEKAR, A., MCMAHAN, K., TOSTANOSKI, L. H., YU, J., GEBRE, M. S., JACOB-DOLAN, C., LI, Z., PATEL, S., PETER, L., LIU, J., BORDUCCHI, E. N., NKOLOLA, J. P., SOUZA, M., TAN, C. S., ZASH, R., JULG, B., NATHAVITHARANA, R. R., SHAPIRO, R. L., AZIM, A. A., ALONSO, C. D., JAEGLE, K., ANSEL, J. L., KANJILAL, D. G., GUINEY, C. J., BRADSHAW, C., TYLER, A., MAKONI, T., YANOSICK, K. E., SEAMAN, M. S., LAUFFENBURGER, D. A., ALTER, G., STRUYF, F., DOUOGUIH, M., VAN HOOF, J., SCHUITEMAKER, H. & BAROUCH, D. H. 2021. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. Jama, 325, 1535-1544.

SUSCHAK, J. J., WILLIAMS, J. A. & SCHMALJOHN, C. S. 2017. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother, 13, 2837-2848.

TAVSAN, S. 2021. Sinovac's COVID-19 shot is 83% effective, not 91%, Turkey says [Online]. Available: https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Sinovac-s-COVID-19-shot-is-83-effective-not-91-Turkey-says [Accessed 24 Juli 2021].

TAYLOR, N. P. 2021. Novavax COVID-19 vaccine 90% efficacious in phase 3, but protection plummets against one variant [Online]. Available: https://www.fiercebiotech.com/biotech/novavax-covid-19-vaccine-90-efficacious-phase-3-but-protection-plummets-against-one-variant [Accessed 24 Juli 2021].

VOYSEY, M., CLEMENS, S. A. C., MADHI, S. A., WECKX, L. Y., FOLEGATTI, P. M., ALEY, P. K., ANGUS, B., BAILLIE, V. L., BARNABAS, S. L., BHORAT, Q. E., BIBI, S., BRINER, C., CICCONI, P., COLLINS, A. M., COLIN-JONES, R., CUTLAND, C. L., DARTON, T. C., DHEDA, K., DUNCAN, C. J. A., EMARY, K. R. W., EWER, K. J., FAIRLIE, L., FAUST, S. N., FENG, S., FERREIRA, D. M., FINN, A., GOODMAN, A. L., GREEN, C. M., GREEN, C. A., HEATH, P. T., HILL, C., HILL, H., HIRSCH, I., HODGSON, S. H. C., IZU, A., JACKSON, S., JENKIN, D., JOE, C. C. D., KERRIDGE, S., KOEN, A., KWATRA, G., LAZARUS, R., LAWRIE, A. M., LELLIOTT, A., LIBRI, V., LILLIE, P. J., MALLORY, R., MENDES, A. V. A., MILAN, E. P., MINASSIAN, A. M., MCGREGOR, A., MORRISON, H., MUJADIDI, Y. F., NANA, A., O'REILLY, P. J., PADAYACHEE, S. D., PITTELLA, A., PLESTED, E., POLLOCK, K. M., RAMASAMY, M. N., RHEAD, S., SCHWARZBOLD, A. V., SINGH, N., SMITH, A., SONG, R., SNAPE, M. D., SPRINZ, E., SUTHERLAND, R. K., TARRANT, R., THOMSON, E. C., TÖRÖK, M. E., TOSHNER, M., TURNER, D. P. J., VEKEMANS, J., VILLAFANA, T. L., WATSON, M. E. E., WILLIAMS, C. J., DOUGLAS, A. D., HILL, A. V. S., LAMBE, T., GILBERT, S. C. & POLLARD, A. J. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397, 99-111.

WALLS, A. C., PARK, Y. J., TORTORICI, M. A., WALL, A., MCGUIRE, A. T. & VEESLER, D. 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281-292.e6.

WALSH, E. E., FRENCK, R. W., JR., FALSEY, A. R., KITCHIN, N., ABSALON, J., GURTMAN, A., LOCKHART, S., NEUZIL, K., MULLIGAN, M. J., BAILEY, R., SWANSON, K. A., LI, P., KOURY, K., KALINA, W., COOPER, D., FONTES-GARFIAS, C., SHI, P. Y., TÜRECI, Ö., TOMPKINS, K. R., LYKE, K. E., RAABE, V., DORMITZER, P. R., JANSEN, K. U., ŞAHIN, U. & GRUBER, W. C. 2020. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med, 383, 2439-2450.

WHO. 2020. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations [Online]. Available: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations [Accessed 23 Juli 2021].

WHO. 2021a. COVID-19 advice for the public: Getting vaccinated [Online]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice [Accessed 21 Juli 2021].

WHO. 2021b. Module 2: Types of Vaccine and Adverse Reactions [Online]. Available: https://vaccine-safety-training.org/overview-and-outcomes-2.html [Accessed 24 Juli 2021].

WHO. 2021c. WHO Coronavirus (COVID-19) Dashboard [Online]. Available: https://covid19.who.int/ [Accessed 10 Agustus 2021].

XIA, S., DUAN, K., ZHANG, Y., ZHAO, D., ZHANG, H., XIE, Z., LI, X., PENG, C., ZHANG, Y., ZHANG, W., YANG, Y., CHEN, W., GAO, X., YOU, W., WANG, X., WANG, Z., SHI, Z., WANG, Y., YANG, X., ZHANG, L., HUANG, L., WANG, Q., LU, J., YANG, Y., GUO, J., ZHOU, W., WAN, X., WU, C., WANG, W., HUANG, S., DU, J., MENG, Z., PAN, A., YUAN, Z., SHEN, S., GUO, W. & YANG, X. 2020. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. Jama, 324, 951-960.

XIA, S., ZHANG, Y., WANG, Y., WANG, H., YANG, Y., GAO, G. F., TAN, W., WU, G., XU, M., LOU, Z., HUANG, W., XU, W., HUANG, B., WANG, H., WANG, W., ZHANG, W., LI, N., XIE, Z., DING, L., YOU, W., ZHAO, Y., YANG, X., LIU, Y., WANG, Q., HUANG, L., YANG, Y., XU, G., LUO, B., WANG, W., LIU, P., GUO, W. & YANG, X. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 21, 39-51.

YADAV, P. D., ELLA, R., KUMAR, S., PATIL, D. R., MOHANDAS, S., SHETE, A. M., VADREVU, K. M., BHATI, G., SAPKAL, G., KAUSHAL, H., PATIL, S., JAIN, R., DESHPANDE, G., GUPTA, N., AGARWAL, K., GOKHALE, M., MATHAPATI, B., METKARI, S., MOTE, C., NYAYANIT, D., PATIL, D. Y., SAI PRASAD, B. S., SURYAWANSHI, A., KADAM, M., KUMAR, A., DAIGUDE, S., GOPALE, S., MAJUMDAR, T., MALI, D., SARKALE, P., BARADKAR, S., GAWANDE, P., JOSHI, Y., FULARI, S., DIGHE, H., SHARMA, S., GUNJIKAR, R., KUMAR, A., KALELE, K., SRINIVAS, V. K., GANGAKHEDKAR, R. R., ELLA, K. M., ABRAHAM, P., PANDA, S. & BHARGAVA, B. 2021. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun, 12, 1386.

ZAKI, A. M., VAN BOHEEMEN, S., BESTEBROER, T. M., OSTERHAUS, A. D. & FOUCHIER, R. A. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 367, 1814-20.

ZHANG, Y., ZENG, G., PAN, H., LI, C., HU, Y., CHU, K., HAN, W., CHEN, Z., TANG, R., YIN, W., CHEN, X., HU, Y., LIU, X., JIANG, C., LI, J., YANG, M., SONG, Y., WANG, X., GAO, Q. & ZHU, F. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21, 181-192.

ZHOU, D., CHAN, J. F., ZHOU, B., ZHOU, R., LI, S., SHAN, S., LIU, L., ZHANG, A. J., CHEN, S. J., CHAN, C. C., XU, H., POON, V. K., YUAN, S., LI, C., CHIK, K. K., CHAN, C. C., CAO, J., CHAN, C. Y., KWAN, K. Y., DU, Z., LAU, T. T., ZHANG, Q., ZHOU, J., TO, K. K., ZHANG, L., HO, D. D., YUEN, K. Y. & CHEN, Z. 2021. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe, 29, 551-563.e5.

ZHU, F. C., GUAN, X. H., LI, Y. H., HUANG, J. Y., JIANG, T., HOU, L. H., LI, J. X., YANG, B. F., WANG, L., WANG, W. J., WU, S. P., WANG, Z., WU, X. H., XU, J. J., ZHANG, Z., JIA, S. Y., WANG, B. S., HU, Y., LIU, J. J., ZHANG, J., QIAN, X. A., LI, Q., PAN, H. X., JIANG, H. D., DENG, P., GOU, J. B., WANG, X. W., WANG, X. H. & CHEN, W. 2020a. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 396, 479-488.

ZHU, F. C., LI, Y. H., GUAN, X. H., HOU, L. H., WANG, W. J., LI, J. X., WU, S. P., WANG, B. S., WANG, Z., WANG, L., JIA, S. Y., JIANG, H. D., WANG, L., JIANG, T., HU, Y., GOU, J. B., XU, S. B., XU, J. J., WANG, X. W., WANG, W. & CHEN, W. 2020b. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 395, 1845-1854.

ZHU, N., ZHANG, D., WANG, W., LI, X., YANG, B., SONG, J., ZHAO, X., HUANG, B., SHI, W., LU, R., NIU, P., ZHAN, F., MA, X., WANG, D., XU, W., WU, G., GAO, G. F. & TAN, W. 2020c. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 382, 727-733.


Article View

Abstract views : 6199 times | PDF files viewed : 28582 times

Dimensions, PlumX, and Google Scholar Metrics

10.33650/jkp.v9i2.2767


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Setiyo Adi Nugroho, Indra Nur Hidayat

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.